Literature DB >> 2909286

Association of sorcin with drug resistance in L1210 cells.

D Roberts1, M B Meyers, J L Biedler, L G Wiggins.   

Abstract

L1210 sublines independently selected for resistance to teniposide (VM-26), etoposide (VP-16), doxorubicin (DOX), dactinomycin (DACT), or vincristine (VCR) express an anionic, 22-kDa protein that is not observed in extracts of parental L1210 cells. Antibody raised against sorcin, an acidic calcium-binding protein overproduced in many other cells resistant to these agents, cross-reacts with the 22-kDa polypeptide. The levels of the 22-kDa protein (sorcin) increase with the relative levels of drug resistance of the L1210 sublines. The appearance of sorcin in these various sublines further supports the notion that the overproduction of this protein is related to the general phenomenon of multidrug resistance rather than to specific drug resistance and that selection for resistance to teniposide produces L1210 sublines with multidrug resistance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2909286     DOI: 10.1007/BF00258452

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.

Authors:  D Roberts; T Lee; E Parganas; L Wiggins; J Yalowich; R Ashmun
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Identification of a novel calcium-binding protein (CP22) in multidrug-resistant murine and hamster cells.

Authors:  G Koch; M Smith; P Twentyman; K Wright
Journal:  FEBS Lett       Date:  1986-01-20       Impact factor: 4.124

4.  Expression of hamster P-glycoprotein and multidrug resistance in DNA-mediated transformants of mouse LTA cells.

Authors:  K L Deuchars; R P Du; M Naik; D Evernden-Porelle; N Kartner; A M van der Bliek; V Ling
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

Review 5.  Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts.

Authors:  W T Beck
Journal:  Cancer Treat Rep       Date:  1983-10

6.  Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.

Authors:  T Lee; D Roberts
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

7.  Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors.

Authors:  Y Pommier; R E Schwartz; L A Zwelling; D Kerrigan; M R Mattern; J Y Charcosset; A Jacquemin-Sablon; K W Kohn
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

8.  Resistance to actinomycin D and to vincristine induced in a SEWA mouse tumor cell line with concomitant appearance of double minutes and a low molecular weight protein.

Authors:  B Dahllöf; T Martinsson; G Levan
Journal:  Exp Cell Res       Date:  1984-06       Impact factor: 3.905

9.  Pleiotropic drug resistance and gene amplification in a SEWA mouse tumor cell line. Complex relations revealed by drug uptake data, and lipid and protein analysis.

Authors:  T Martinsson; B Dahllöf; Y Wettergren; H Leffler; G Levan
Journal:  Exp Cell Res       Date:  1985-06       Impact factor: 3.905

10.  A 22-kd protein (sorcin/V19) encoded by an amplified gene in multidrug-resistant cells, is homologous to the calcium-binding light chain of calpain.

Authors:  A M Van der Bliek; M B Meyers; J L Biedler; E Hes; P Borst
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

View more
  2 in total

1.  Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance.

Authors:  D W Roberts; P D Foglesong; E Parganas; L Wiggins
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Sorcin a Potential Molecular Target for Cancer Therapy.

Authors:  Bano Shabnam; Ganesan Padmavathi; Kishore Banik; Sosmitha Girisa; Javadi Monisha; Gautam Sethi; Lu Fan; Lingzhi Wang; Xinliang Mao; Ajaikumar B Kunnumakkara
Journal:  Transl Oncol       Date:  2018-09-11       Impact factor: 4.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.